KX2-391 Dihydrochloride: Dual Src Kinase and Tubulin Inhibitor for Oncology and HBV Research

Executive Summary: KX2-391 dihydrochloride (also known as Tirbanibulin dihydrochloride or KX-01 dihydrochloride) is a potent, small-molecule inhibitor targeting the Src kinase and tubulin polymerization pathways with nanomolar-range IC₅₀ values in cell models (Harada et al., 2017). It displays a unique dual mechanism, inhibiting Src via substrate-binding site interaction and blocking tubulin polymerization through a novel α-β heterodimer site. KX2-391 demonstrates anti-HBV activity by suppressing transcription from the HBV precore promoter, independent of Src inhibition, and inhibits botulinum neurotoxin A (BoNT/A) activity at micromolar concentrations (APExBIO). The compound shows favorable in vivo tolerability, with no significant peripheral neuropathy in clinical settings, and is suitable for a range of oncology, antiviral, and neurobiology workflows. Storage recommendations and solubility parameters ensure reliable use in laboratory protocols.

Biological Rationale

KX2-391 dihydrochloride was developed to address the need for selective inhibitors of the Src kinase signaling pathway, which is implicated in cancer cell proliferation, survival, and metastasis (Harada et al., 2017). Src kinase is upregulated in various tumors and plays a central role in cellular motility, angiogenesis, and invasion. Tubulin polymerization is essential for mitotic spindle formation and cell division. Inhibiting this process can halt cell proliferation in cancer and viral-infected cells. The dual activity of KX2-391 also enables it to suppress HBV transcription, a critical step in the viral replication pathway, thereby providing an alternative to nucleos(t)ide analogs that do not eliminate cccDNA reservoirs (see related article; this review extends the mechanistic focus to HBV-specific transcriptional suppression).

Mechanism of Action of KX2-391 dihydrochloride

• Src kinase inhibition: KX2-391 binds to the substrate-binding site of Src kinase, preventing downstream signal transduction involved in oncogenic processes (DOI).
• Tubulin polymerization inhibition: The compound interacts with a novel site on the α-β tubulin heterodimer, distinct from classic tubulin inhibitors, disrupting microtubule assembly (inhibition observed ≥80 nM in vitro) (APExBIO).
• HBV transcription suppression: KX2-391 inhibits HBV transcription by targeting the precore promoter, independent of Src kinase activity (siRNA knockdown of Src does not abrogate KX2-391 effect) (Harada et al., 2017).
• BoNT/A light chain inhibition: At 10–40 μM, KX2-391 inhibits BoNT/A by blocking SNAP-25 cleavage (APExBIO).

Evidence & Benchmarks

• KX2-391 inhibits Src kinase with IC₅₀ values of 23 nM (NIH3T3/c-Src527F cells) and 39 nM (SYF/c-Src527F cells) (Harada et al., 2017).
• In vitro tubulin polymerization inhibition is observed at concentrations ≥80 nM (Harada et al., 2017).
• Anti-HBV activity is demonstrated with EC₅₀ of 0.14 μM in PXB cells and 2.7 μM in HepG2-NTCP cells, with selectivity indices of 450 and >37, respectively (DOI).
• Oral dosing in mice (oncology) is effective at 5–15 mg/kg once or twice daily; in chimpanzees (anti-HBV), 1 mg/kg twice daily achieves plasma levels >560 nM (241.92 ng/mL) (APExBIO).
• KX2-391 is well tolerated clinically, with topical 1% ointment for actinic keratosis and oral doses of 40–120 mg/day yielding plasma C_max 61–218 ng/mL; no significant peripheral neuropathy reported (APExBIO).

Applications, Limits & Misconceptions

KX2-391 dihydrochloride is broadly applied in cancer research, HBV replication studies, and neurotoxin pathway analysis. Its use is supported in in vitro, in vivo, and clinical contexts.

• Oncology: Effective in cell-based assays targeting Src kinase and tubulin polymerization pathways. Typical concentrations: 0.013–10 μM.
• HBV research: Used to dissect HBV transcriptional regulation and replication. Effective at submicromolar to low micromolar concentrations.
• Neurotoxin studies: Inhibits BoNT/A light chain at higher micromolar concentrations (10–40 μM).

For detailed protocol adaptations within cytotoxicity, proliferation, and viability assays, see this article, which our current review updates with new clinical tolerability and anti-HBV selectivity data.

Common Pitfalls or Misconceptions

• KX2-391 dihydrochloride is not effective against HBV cccDNA elimination; it suppresses HBV transcription but does not remove viral DNA reservoirs (Harada et al., 2017).
• Its anti-HBV effect is independent of Src kinase inhibition; tubulin polymerization inhibition is the primary mechanism for viral suppression.
• Compound is insoluble in water; use DMSO or ethanol (with gentle warming) at ≥25.2 mg/mL and ≥48.8 mg/mL, respectively (APExBIO).
• Long-term storage in solution is not recommended; prepare fresh aliquots for each experiment.
• Clinical and in vivo anti-HBV efficacy requires plasma concentrations ≥560 nM; subtherapeutic dosing may yield false negatives.

Workflow Integration & Parameters

KX2-391 dihydrochloride (SKU A3535) from APExBIO is standardized for reproducible research. For cell-based studies, prepare stock solutions in DMSO or ethanol. Recommended working concentrations:

• Anticancer and anti-HBV studies: 0.013–10 μM (in vitro).
• Anti-BoNT/A assays: 10–40 μM.
• In vivo (mice): 5–15 mg/kg, oral, once or twice daily.
• In vivo (chimpanzee, anti-HBV): 1 mg/kg, twice daily.
• Clinical (topical): 1% ointment (10 mg/g), applied once daily for 5 days.
• Clinical (oral): 40–120 mg/day yields C_max 61–218 ng/mL.

See KX2-391 dihydrochloride product page for lot-specific documentation, and this application guide for scenario-driven workflow optimization—this article expands on selectivity indices and tolerability.

Conclusion & Outlook

KX2-391 dihydrochloride is a validated dual-mechanism inhibitor with applications in cancer biology, HBV research, and neurotoxin studies. Its unique targeting of Src kinase and tubulin polymerization, alongside robust tolerability, underscores its value for translational and mechanistic studies. Future research will clarify its role in combinatorial regimens and novel viral models. For a deeper mechanistic analysis, see this comprehensive review; the present article emphasizes clinical and selectivity data not previously covered.

APExBIO provides high-purity KX2-391 dihydrochloride for research use (SKU A3535), with detailed support for oncology and antiviral workflows.